Your session is about to expire
← Back to Search
Ravulizumab for Neuromyelitis Optica Spectrum Disorders
Study Summary
This trialstudies a drug to help children with a rare disorder affecting the brain and spinal cord.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2022 Phase 3 trial • 195 Patients • NCT03056040Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have had at least one attack or relapse of my condition in the past year and have not received complement inhibitor treatment.I have not used rituximab in the last 6 months.I am vaccinated against meningococcal infection.I am positive for anti-AQP4 antibodies and have been diagnosed with NMOSD.I am on a stable dose of medication to prevent my condition from returning.My disability score is 7 or less.I am on, or recently stopped, a biologic medication that affects my immune system.I have been stable on eculizumab for 30 days and took it for at least 90 days without missing doses in the last 2 months.I have been vaccinated for Hib and S pneumoniae according to my country's guidelines.I haven't used MS immunotherapy in the last 3 months.I haven't had IVIg or plasma exchange in the last 3 weeks.
- Group 1: Ravulizumab
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
How many test subjects are actively participating in this experiment?
"The clinical trial is enrolling 12 patients between 1 sites."
How can I get involved in this research project?
"This clinical trial is admitting 12 participants, within the ages of 2 and 17 who have neuromyelitis optica. It is important that patients also meet the following criteria: Participants must be anti-AQP4 Ab-positive and have a diagnosis of NMOSD as defined by the 2015 international consensus diagnostic criteria., Complement inhibitor treatment-naïve participants must have had at least 1 attack or relapse in the last 12 months prior to the Screening Period., Expanded Disability Status Scale (EDSS) score ≤ 7., Eculizumab-experienced participants must be clinically stable per Investigator for 30 days and have been"
Are we still looking for participants in this research?
"The study is currently ongoing and actively recruiting patients, as reflected in the clinicaltrials.gov posting from June 23rd, 2022 to November 4th, 2022."
Does this clinical trial have an age limit? If so, what is it?
"This particular study is only enrolling patients aged 2-17, however there are 6 other trials for pediatric patients and 16 clinical trials for elderly patients."
Who else is applying?
What portion of applicants met pre-screening criteria?
Why did patients apply to this trial?
Share this study with friends
Copy Link
Messenger